ReviewMediterranean journal of rheumatology2017
Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies.
Review in Mediterranean journal of rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Pooled it
- Anesthesia in systemic lupus erythematosus: a review of key considerations and surgical challenges.Perioperative medicine (London, England) · 2026Review
- Article
- Patient-Reported Flare Symptoms Following COVID-19 Vaccination in Systemic Lupus Erythematosus.Cureus · 2026Article
- Epidemiology and prognosis of childhood lupus nephritis in the Afro-descendant population of the French Overseas Departments of America.BMC nephrology · 2026Article
- Allergic reactions in systemic lupus erythematosus: From pathogenic pathways to clinical practice.Asia Pacific allergy · 2026Review
- Article
- Validity of a claim-based algorithm for classifying disease activity levels using Systemic Lupus Erythematosus Disease Activity Index 2000 in Korean patients with systemic lupus erythematosus.Journal of rheumatic diseases · 2025Article
- From reactive to proactive: Continuous protein monitoring for preventive health care.Science (New York, N.Y.) · 2025Review
- The Lupus Check 5 Tool: A Practical Approach to Initiating Treatment Reviews in Systemic Lupus Erythematosus.Rheumatology and therapy · 2025Article
- Validation of childhood lupus specific targets: ensuring accurate assessment of disease control in younger, lighter paediatric patients.Rheumatology (Oxford, England) · 2025Article
- Prediction of Lupus Classification Criteria via Generative AI Medical Record Profiling.Biotech (Basel (Switzerland)) · 2025Article
- Article
- A serum biomarker panel and miniarray detection system for tracking disease activity and flare risk in lupus nephritis.Frontiers in immunology · 2025Article
- Disparities in Peripheral Artery Disease-related Mortality in Chronic Inflammatory Disease in the United States from 1999 to 2020.Current cardiology reviews · 2025Article
- Identifying meaningful aspects of health and concepts of interest for assessment in systemic lupus erythematosus: implications for digital clinical measure development.Journal of patient-reported outcomes · 2024Article
- Urinary Immune Complexes Reflect Renal Pathology in Lupus Nephritis.Diagnostics (Basel, Switzerland) · 2024Article
- Circulating B Lymphocyte Subsets in Patients with Systemic Lupus Erythematosus.Medicina (Kaunas, Lithuania) · 2024Article
- Observational
- Clinical characteristics and risk factors for lupus flares in sub-Saharan Africa-retrospective cross-sectional study.Clinical rheumatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in the treatment, patients with systemic lupus erythematosus (SLE) often experience disease exacerbations (flares) of varying severity. Their diagnosis is primarily made on clinical grounds after exclusion of other diseases or disturbances, primarily infections, and can be assisted by the use of validated clinical indices. Serological tests such as serum complement fractions and anti-dsDNA autoantibodies, are helpful in monitoring SLE activity, but they lack high diagnostic accuracy. Flares are more frequent in patients with persistent immunological and clinical activity, and have been described as significant risk factor for development of irreversible end-organ damage. Accordingly, prevention of flares has been recognized as a distinct therapeutic target in SLE and involves adequate control of disease activity, use of hydroxychloroquine, maintaining immunosuppressive or biologic therapy for several years, and avoiding non-compliance issues. The future holds promise for the discovery of biomarkers that will accurately predict or diagnose SLE flares, thus allowing for the implementation of patient-tailored preventive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.